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Summary
Background—While laboratory aetiological diagnosis is considered the gold standard for 
diagnosis and management of sexually transmitted infections, syndromic management has been 
presented as a simplified and affordable approach for sexually transmitted infection management 
in limited resource settings.
Methods—Sexually transmitted infection signs and symptoms were collected using staff-
administered computer-assisted personal interview and audio computer-assisted self-interview. 
Participants underwent a medical examination and laboratory testing for common sexually 
transmitted infections. The performance of syndromic management was assessed on the agreement 
between interviewing methods as well as accurate diagnosis.
Results—We screened 846 participants, of whom 88 (10.4%) received syndromic sexually 
transmitted infection diagnosis while 272 (32.2%) received an aetiological diagnosis. Agreement 
between syndromic and aetiological diagnoses was very poor (overall kappa = 0.09). The most 
prevalent sexually transmitted infection was herpes simplex virus type 2 and the percentage of 
persons with any sexually transmitted infection was higher among women (48.6%) than men 
(15.6%, p <0.0001). Agreement between audio computer-assisted self-interview and computer-
assisted personal interview interviewing methods for syndromic diagnosis of sexually transmitted 
infections ranged from poor to good.
Conclusion—Our findings suggest that syndromic management of sexually transmitted 
infections is not a sufficient tool for sexually transmitted infection diagnosis in this setting; 
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development and improvement of sexually transmitted infection diagnostic capabilities through 
laboratory confirmation is needed in resource-limited settings.
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Introduction
The World Health Organization (WHO) estimates that more than 448 million incident cases 
of curable sexually transmitted infections (STIs) (syphilis, gonorrhoea, chlamydia and 
trichomoniasis) occur annually throughout the world. Addition of herpes simplex virus type 
2 (HSV-2) to this tally will significantly increase this number.1–3 Sub-Saharan Africa 
continues to bear the greatest burden of these STIs.4–6 STIs are an important cause of 
morbidity and mortality among African populations, resulting in adverse birth outcomes, 
neonatal and infant infections, ectopic pregnancy, anogenital cancer, infertility, pelvic 
inflammatory disease and death.3,7–9 STIs may also facilitate the transmission of HIV by 
augmenting HIV infectiousness and HIV susceptibility via a variety of biological 
mechanisms.10–17 STI diagnosis and treatment needs to be prompt and accurate to 
effectively control their spread and to minimise associated morbidity and mortality.9
The proper management of STIs should include strategies for screening patients, partner 
notification, the administration of mono-dose and simplified therapies to improve 
compliance and increasing the accessibility of services.18 The introduction of new 
diagnostic tools and algorithms has improved STI management considerably. The WHO 
provides recommendations on these diagnostic tools and algorithms that different regions 
and countries may adapt.3,8 Aetiological diagnosis using laboratory confirmation is 
considered the gold standard for the diagnosis and management of STIs19; however, it is not 
always a practical strategy and may result in delayed treatment and increased loss to follow-
up. Moreover, many health care facilities in developing countries lack the equipment and 
trained personnel required to perform aetiological diagnosis of STIs.
To overcome this problem, a syndrome-based approach to the management of STI patients 
has been developed and promoted in a large number of countries in the developing world as 
a simplified and affordable approach for the diagnosis of STIs. The syndromic management 
approach is based on the identification of consistent groups of clinical symptoms and easily 
recognised signs (syndromes), and the provision of treatment that will deal with the majority 
or the most serious, organisms responsible for producing a syndrome. The WHO developed 
a simplified algorithm to guide health workers in the implementation of syndromic 
management of STIs and in 2003, the WHO guidelines were revised to focus exclusively on 
syndromic management.8 Kenya, along with other countries, adapted these guidelines for 
the national programme.20,21
Ideally, syndromic management removes the need for laboratory testing and extra clinic 
visits for follow-up, which may result in treatment delays3 and to some extent the need for a 
physical examination.22 This approach is viewed as a practical strategy for use in resource-
limited settings as it provides prompt treatment and helps avoid potential loss to follow-up 
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observed in STI management involving laboratory-based diagnosis.23 Moreover, the 
practice may be necessary in cases where pathogen detection is difficult such as with upper 
genital tract infections.22
The literature has shown that the syndromic approach to the management of STIs can be 
effective16,24–26; however, most of these evaluations have focused on syndromic STI 
management within STI clinics. In this context, the probability of having an STI is relatively 
high because patients often self-select and present for evaluation with STI-specific signs and 
symptoms. By contrast, there are few evaluations of syndromic STI management within 
research contexts in which all study participants are routinely asked questions about STI-
specific signs and symptoms. Because syndromic management is also carried out within a 
research context, it is important to determine if it is a sufficient tool for diagnosing STIs or 
whether it must be paired with laboratory testing.
In January 2007, the Kenya Medical Research Centre (KEMRI) in collaboration with the 
Centers for Disease Control and Prevention (CDC) initiated an HIV incidence cohort study 
to prepare for future community-based HIV vaccine or other prevention trials among young 
adults in Kisumu. We utilised data from the screening visit for this cohort to evaluate if the 
syndromic management of STIs is a sufficient tool for the diagnosis and management of 
STIs in a research setting and to compare the methods for the collection of symptom data.
Methods
Study population and procedures
Between January 2007 and March 2009, 1277 individuals were screened and 846 were 
enrolled into the Kisumu Incidence Cohort Study (KICoS), an observational prospective 
cohort study to estimate the incidence of HIV seroconversion and to identify determinants of 
successful recruitment and retention.27 Adults 18–34 years of age, residents of Kisumu, 
HIV-negative at baseline, not pregnant (women only), and reported having had sexual 
intercourse at least once in the past three months were eligible for study participation.
Demographic and behavioural information were collected from screened participants using 
both staff-administered computer-assisted personal interview (CAPI) and participant self-
administered audio computer-assisted self-interview (ACASI). While STI signs were 
detected by a clinician and documented in CAPI, symptoms were collected through both 
ACASI and CAPI. In both interviews, participants were asked whether they had symptoms 
of vaginal or urethral discharge, lower abdominal or scrotal pain or genital ulcers. Following 
the CAPI interview, a clinician performed a physical examination for signs to match the 
collected symptoms. Blood, urine and vaginal swab samples were collected for laboratory 
testing for gonorrhoea, chlamydia, syphilis and HSV-2, regardless of symptoms or signs. In 
addition, rapid HIV testing with pre- and post-test counselling was also done for all 
participants. An appointment was scheduled two weeks thereafter to deliver laboratory STI 
results.
Participants were diagnosed at the screening visit and given immediate treatment using the 
Kenya national guidelines on syndromic management for STIs (Figure 1).21 Definitive 
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treatment was offered as necessary when laboratory results became available. Participants 
receiving syndromic or definitive treatment also received contact treatment cards to give to 
their sexual partners. These contact cards had no identifying information and were coded 
with names of animals and fruits to correlate with STI syndromes or diagnoses. Sexual 
partners were required to present these cards to the clinic to receive anonymous presumptive 
treatment services.
Syphilis testing was performed using BD Micro-Vue™ RPR (rapid plasma reagin) Card test 
and all reactive tests confirmed by Serodia® TP-PA Syphilis Test. HSV-2 serology was 
tested using KALON® HSV-2 IgG enzyme-linked immunoassay and infection with 
Chlamydia trachomatis or Neisseriae gonorrhoeae was evaluated by qualitative polymerase 
chain reaction using COBAS® AMPLICOR CT/NG (Roche). Real-time parallel rapid HIV 
testing was conducted using Trinity Biotech® Uni-Gold HIV-1/2, and Abbott Labs® 
Determine HIV-1/2; [tie breaker with Meridian Life Science® Bioline].
Ethical approval
This study was approved by the KEMRI Scientific Steering Committee and Ethical Review 
Committee and the CDC Institutional Review Board. All participants provided written 
informed consent to screen for eligibility and take part in the study in one of the three 
languages of their preference: English, Dholuo or Swahili. Participants received a standard 
transport reimbursement of KES 300 (USD 3.50). In addition, they received treatment for 
STIs and other common ailments as well as provision of condoms (male and female).
Measures
Syndromic diagnosis for urethritis/vaginitis/cervicitis was based on having urethral 
discharge and self-reported scrotal pain for men, and vaginal discharge and/or pruritus and 
self-reported lower abdominal pain for women. Genital ulcer disease (GUD) was based on 
reports of ulcers in the genitalia for both men and women. For ascribing syndromic 
diagnoses to aetiological diagnosis, urethritis, cervicitis, lower abdominal pain and scrotal 
pain were attributed to gonorrhoea and chlamydia, while vaginitis was attributed to Candida 
and trichomonas. GUD was ascribed to chancroid, syphilis and HSV-2. Syndromic 
diagnoses were based on signs and symptoms collected in CAPI but not ACASI, while 
aetiological diagnoses were based on laboratory testing.
Data analysis
Summary statistics were used to describe the sociodemographic characteristics of 
participants. We compared different groups with chi square statistics and calculated the 
syndromic and aetiological prevalence of STIs with 95% confidence intervals. We computed 
a kappa coefficient28,29 to evaluate the agreement between reporting symptoms of STIs 
between ACASI and CAPI as well as that of STI diagnoses by syndromic management 
versus a laboratory-based diagnosis. We also computed the positive and negative predictive 
values (NPVs) for STI diagnosis using laboratory-based aetiological diagnosis as the gold 
standard. Data analysis was performed using SAS version 9.2 (SAS, Cary, North Carolina, 
USA).
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The 846 participants screened for enrolment in KICoS had a median age of 23 years; almost 
two-thirds (62.7%) were 20–24 years of age. Half (50.1%) were women, and the majority 
were Christians (81.4%), had never been married (61.2%), and had either secondary or post-
secondary educational attainment levels (70%) (Table 1).
STI prevalence
Overall, 10.4% (n = 88) of participants were diagnosed with an STI through the clinician-
based syndromic diagnosis compared to 32.2% (n = 272) who received an aetiological STI 
diagnosis through laboratory confirmation. The prevalence of STIs was greater among 
women than men for both the syndromic diagnosis (17.2% vs. 3.6%, p <0.0001) and the 
aetiological diagnosis (48.6% vs. 15.6%, p <0.0001). Based on the aetiological diagnosis, 
HSV-2 was the most prevalent STI (29.1%) followed by chlamydia (2.8%), gonorrhoea 
(2.4%) and syphilis (1.7%). Lower abdominal/ scrotal pain was the most prevalent syndrome 
(5.9%) followed by vaginal/urethral discharge (5.3%) and GUD (1.7%). Among the 272 
participants with a laboratory-diagnosed STI, 30 (11.0%) had two STIs while one (0.4%) 
had three STI co-infections at the time of diagnosis (Table 2). Overall, HIV prevalence was 
14.5% with a disproportionate rate of infection among women (21.2%) compared to men 
(7.8%, p <0.0001).
Comparison of ACASI versus CAPI
The performance of syndromic management was assessed on both the agreement between 
interviewing methods as well as accurate diagnosis. The agreement between the ACASI and 
CAPI methods of interviewing for the syndromic diagnosis of STIs varied, with agreement 
on the diagnosis of GUD and vaginal/urethral discharge at kappas of 0.26 and 0.34, 
respectively, and for that of lower abdominal/scrotal pain at kappa of 0.65. More 
participants reported symptoms in ACASI compared to CAPI, with 8.1% reporting lower 
abdominal/scrotal pain in ACASI compared to 4.9% (p <0.0001) in CAPI. More participants 
also reported genital ulcers (7.0%) and vaginal/urethral discharge (4.6%) through ACASI 
than CAPI (2.3%, p <0.0001 and 1.4, p <0.0001, respectively) (Table 3).
Performance of syndromic management
The agreement between the clinician-based syndromic diagnosis and the laboratory 
aetiological diagnosis had an overall kappa of 0.09. This was similar even when we dropped 
HSV-2 and syphilis from the model. The positive predictive value (PPV) of syndromic 
diagnosis was 50.6% overall, with syphilis being the lowest at 0.0% and HSV-2 being the 
highest at 63.6%. However, when we dropped HSV-2 and syphilis, the overall PPV dropped 
to 11.3%. The NPV was 67.2% overall, with HSV-2 being the lowest at 69.0% and syphilis 
being the highest at 98.3%. However, the overall NPV increased to 95.7% when we dropped 
HSV-2 and syphilis from the model (Table 4). HSV-2 was severely underdiagnosed using 
the syndromic management approach (1.4%) as compared to laboratory-based diagnoses 
(29.1%, p = 0.04), while gonorrhoea and chlamydia were overdiagnosed using syndromic 
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management (9.5% for both) compared to laboratory-based diagnoses (2.4%, p = 0.008 and 
2.8%, p = 0.27, respectively). The same number of syphilis diagnoses occurred with each 
method (n = 14), however, not among the same 14 participants (Table 4).
Partner notification and treatment
A total of 54 participants, eight men and 46 women, were issued contact tracing cards 
following their syndromic management diagnosis. Among these participants, only one 
partner showed up for contact evaluation and treatment. Of the 272 participants issued with 
contact tracing cards following aetiological diagnosis, one partner presented for evaluation 
and treatment.
Discussion
These data show that the aetiological prevalence of STIs is very high among persons 
screened for KICoS. HSV-2 was the most prevalent STI, found across all STI co-infections 
observed in the study. The majority of STI infections (75.7%) were found in women, 
consistent with findings from other studies conducted in the same general geographical 
location.5,30–32 Overall, the majority of STI diagnoses were missed on syndromic diagnosis 
alone, indicating that laboratory tests are still needed to diagnose and confirm infection in 
this setting. HSV-2 was severely underdiagnosed using the syndromic management 
approach, while gonorrhoea and chlamydia were overdiagnosed.
There may be several reasons why the syndromic approach to the management of STIs was 
not effective in our study. First, most of the evaluations that have shown success using 
syndromic management were performed within STI clinics.16,24–26 In this context, the 
probability of having an STI is relatively high because patients often self-select and present 
for evaluation with STI-specific signs and symptoms. By contrast, persons who screen and 
enrol in research studies provide a better representation of the burden of disease and 
prevalence of both symptomatic and asymptomatic infection among the general population. 
STI clinics thus still present one of the most appropriate avenues for the use of syndromic 
diagnosis as it captures symptomatic acute STIs such as gonorrhoea and chlamydia as well 
as active HSV-2 and syphilis, which arguably have more impact on morbidity/mortality and 
the need to rely on laboratory studies to diagnose latent STI such as latent HSV and syphilis. 
In general, it seems optimal that the syndromic management algorithms overdiagnose 
chlamydia/gonorrhoea which likely results in fewer missed treatment opportunities.
The high prevalence of asymptomatic infection for STIs has been well documented in 
literature.33–35 Asymptomatic infection is problematic because patients not having 
symptoms are less likely to seek medical care; and among those who do, they are less likely 
to get tested for the STIs. In order for the syndromic management approach to be effective, 
health care providers must have a basis for diagnosing and treating disease through 
symptoms and/or signs. In our study, STI diagnoses that were missed through syndromic 
management appeared to reflect asymptomatic infection or lack of disclosure of symptoms 
among study participants.
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Because few evaluations of syndromic STI management within research contexts routinely 
ask all study participants questions about STI-specific signs and symptoms, we have a 
limited ability to compare our findings with other studies. Among the studies that have been 
done in research settings, some algorithms have been shown to work, including those for 
urethral discharge and GUD, while others have performed poorly, such as those for 
chlamydia and gonorrhoea.36–39 These findings suggest that laboratory screening of STIs 
should occur regardless of reported symptoms or condom use. Prevention efforts should 
focus on increasing awareness of asymptomatic STI infection among providers and the 
community. Left untreated, these infections could be co-factors in the transmission of HIV 
as well as contributors to increased morbidity and mortality3,7–9
Ensuring that appropriate STI screening occurs requires non-judgmental risk assessments of 
all patients. Although the syndromic diagnosis is based on the signs and symptoms collected 
through the CAPI, we included ACASI responses in this analysis to compare the symptoms 
that were reported through ACASI to those reported through CAPI. We hypothesised that 
persons would be more forthcoming with sharing information pertaining to sexual behaviour 
and risk through the self-administered ACASI, as compared to clinician-based CAPI. This 
was found to be true as more participants reported symptoms in ACASI as compared to 
CAPI. This might present an opportunity for capturing more syndromic STI cases that 
would otherwise be lost as individuals might not be forthcoming when faced by a clinician 
or another staff asking for them.
There have been significant changes and improvements in STI testing technologies and 
diagnostic capabilities in the past decade; however, further work is needed to develop and 
improve upon point-of-care tests (POCT) for STIs.40,41 The implementation of POCTs at 
healthcare facilities would be ideal as they have fast processing times and would allow 
patients to receive their test results and the necessary treatment in the same visit, resulting in 
lower rates of loss to follow-up. Further, a POCT for STIs would support the WHO sexually 
transmitted diseases diagnostics initiative (WHO SDI). This initiative has identified criteria 
for an STI POCT as being: affordable, sensitive, specific, user-friendly, rapid and robust, 
equipment-free and deliverable to end-users.42
An essential component of STI control is partner treatment. This has been implemented 
through ‘partner notification’, which involves notifying the partner of their exposure to an 
STI followed by a recommendation for the partner to seek evaluation and treatment, if 
necessary.43 The primary goals of partner notification are identifying and treating new cases 
of STIs and providing prophylactic treatment to individuals who have had an exposure.44 In 
developed countries, the responsibility of notifying the patient has typically fallen on trained 
public health professionals; however, this method is costly and labour-intensive and many 
developing countries lack the resources and infrastructure necessary for successful 
implementation.45 Instead, the most common alternative notification method is ‘patient 
referral’ where providers encourage patients to notify their own sexual partners and refer 
them for treatment. In our study, the number of partners that presented for evaluation and 
treatment was very low, indicating poor rates of partner notification and/or partners coming 
for treatment. In developing countries and resource-limited settings, strategies such as 
strengthened education and counselling services, especially toward women in maternal 
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health or family planning clinics, contact cards, educational materials, follow-up and 
financial incentives may be necessary to increase partner notification.45
There are several limitations to consider when interpreting our findings. First, our 
participants may not be representative of the Kisumu population, since they were volunteers 
for a research study and were recruited through convenience sampling. However, HIV 
prevalence found at the screening visit was nearly identical to local population estimates 
from national surveillance data, suggesting that the study participants may be representative 
of the local community.32 Second, as with any self-reported behavioural surveys, response 
bias may have been present. We tried to control for this through the use of ACASI, which 
has been reported to facilitate more accurate responses to sensitive behavioural questions 
than face-to-face interviews.46,47 Third, the aetiological diagnosis of chlamydia and 
gonorrhoea used an assay for active disease; however, the HSV-2 and syphilis serology may 
have misclassified recent acquisition as it also classifies people as positive even if their 
infection was remote and is inactive.48–51 Further, the misclassification of symptom status 
could have occurred if the reported symptoms were unrelated to gonorrhoea, chlamydia, 
syphilis or HSV-2 but to other organisms that were not tested for example mycoplasma 
genitalium, trichomonas vaginalis, etc.
These data show that more participants reported symptoms in ACASI as compared to CAPI. 
This presents a challenge on the applicability of this methodology in research and non-
research settings as the current algorithms require for a clinician-based evaluation of signs in 
addition to the reported symptoms.3,8 Further, the syndromic management of STIs is not a 
sufficient tool for STI diagnosis in this setting; laboratory tests are still needed to diagnose 
and confirm infection. Further, work is needed to develop and improve upon STI diagnostic 
capabilities in resource-limited settings, address asymptomatic infection, and improve STI 
management including partner notification and referral in research settings. This will 
improve point-of-care testing with reduced turnaround time of tests and patient retention.
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Table 1
Demographic characteristics of participants completing KICoS screening in Kisumu, Kenya (2007–2008)
Characteristic n/Na Percentage
Gender
 Men 422/846 49.9
 Women 424/846 50.1
Age group (years)
 18–19 105/846 12.4
 20–24 530/846 62.7
 25–29 149/846 17.6
 30–34 62/846 7.3
Marital status
 Single/never married 515/842 61.2
 Married/not married but living as married 286/842 34.0
 Separated/divorced/widowed 41/842 4.9
Ethnic group or tribe
 Luo 709/845 83.9
 Luhya 80/845 9.5
 Kisii 33/845 3.9
 Kikuyu/maasai/other 23/845 2.7
Religion
 Roman catholic 318/846 37.6
 Protestant or other Christian 370/846 43.8
 Muslim/nomiya/other 132/846 15.6
 No religion 25/846 3.0
Highest education level
 Never attended school/primary school 254/842 30.2
 Secondary school 311/842 36.9
 Post-secondary school 277/842 32.9
Occupation
 Salaried worker 22/841 2.6
 Self-employed/casual worker 263/841 31.3
 Students, not otherwise employed 279/841 33.2
 Other (includes farmer) 54/841 6.4
 Not employed (includes homemaker) 223/841 26.5
Lifetime number of sexual partners
 0–1 partner 111/808 13.7
 2–3 partners 269/808 33.3
 ≥ 4 partners 428/808 53.0
a
Sample sizes fluctuate slightly for some variables due to missing data. Some percentages do not sum to 100 due to rounding.
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